Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
RFK Jr. releases new dietary guidelines with emphasis on protein, full-fat dairy - 2Make your choice for a definitive Christmas place to get-away!
- 3Report in relation to renaming Herzog Park set to be withdrawn
- 4Figure out How to Modify Your Pre-assembled Home for Greatest Solace and Stylish Allure
- 5Toddler diagnosed with cancer makes remarkable recovery after aggressive treatment
- Gen Z workplace stereotypes were TV’s favorite punchline in 2025
- The Most Astonishing Arising Advances to Watch
- Forget 'Outer Banks.' These Gen Z-ers just want to watch 'M*A*S*H*' and 'Gilmore Girls.'
- Flourishing in a Remote Workplace: Individual Techniques
- Nations for Youngsters to Visit
- Scientists find twisting magnetic waves on the sun. Could this help solve a huge solar mystery?
- I served on the expert committee that advised the government on new dietary guidelines – most of our recommendations were ignored
- A NASA spacecraft orbiting Mars may be dead
- Space debris: will it take a catastrophe for nations to take the issue seriously?
